SCHEMBL311445

SCHEMBL311445

CCCc1cc(F)ccc1[N+](=O)[O-]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPT P10636 6/20 0.46
ALDH1A1 P00352 5/20 0.46
MAPK1 P28482 1/20 0.46
SNCA P37840 3/20 0.42
LMNA P02545 1/20 0.39
XBP1 P17861 1/20 0.39
HIF1A Q16665 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
F2RL1 P55085 3/20 0.39
HSPB1 P04792 2/20 0.39
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE7A Q13946 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310839 0.87 TDP1 (0.60) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL29362511 0.87 TDP1 (0.60) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL17870695 0.83 TDP1 (0.59) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL6489968 0.83 ATM (0.55) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL27780316 0.83 TDP1 (0.55) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL5194061 0.83 TDP1 (0.55) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL26803674 0.81 ATM (0.49) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL27865322 0.81 CYP1A2 (0.50) TDP1MAPTALDH1A1MAPK1LMNA
SCHEMBL3515439 0.80 ATM (0.56) ATMTDP1MAPTALDH1A1MAPK1
SCHEMBL13262511 0.79 ATM (0.55) ATMTDP1MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
CN-101932580-A Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC 2010-12-29 CN disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ATM 724/4885TDP1 1064/4885MAPT 2367/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ATM 724/4885TDP1 1064/4885MAPT 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.